GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Biolase Inc (OTCPK:BIOLQ) » Definitions » Beneish M-Score

BIOLQ (Biolase) Beneish M-Score : -3.08 (As of Dec. 12, 2024)


View and export this data going back to 1992. Start your Free Trial

What is Biolase Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -3.08 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Biolase's Beneish M-Score or its related term are showing as below:

BIOLQ' s Beneish M-Score Range Over the Past 10 Years
Min: -4.46   Med: -2.79   Max: -1.6
Current: -3.08

During the past 13 years, the highest Beneish M-Score of Biolase was -1.60. The lowest was -4.46. And the median was -2.79.


Biolase Beneish M-Score Historical Data

The historical data trend for Biolase's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biolase Beneish M-Score Chart

Biolase Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.40 -3.64 -2.54 -2.13 -3.43

Biolase Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.49 -3.43 -3.22 -3.81 -3.08

Competitive Comparison of Biolase's Beneish M-Score

For the Medical Devices subindustry, Biolase's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biolase's Beneish M-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Biolase's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Biolase's Beneish M-Score falls into.



Biolase Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Biolase for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.8691+0.528 * 0.9809+0.404 * 1.4179+0.892 * 0.9256+0.115 * 0.6237
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.8346+4.679 * -0.093315-0.327 * 1.3774
=-3.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep24) TTM:Last Year (Sep23) TTM:
Total Receivables was $3.53 Mil.
Revenue was 10.85 + 11.555 + 10.131 + 13.49 = $46.03 Mil.
Gross Profit was 4.382 + 4.609 + 3.336 + 3.524 = $15.85 Mil.
Total Current Assets was $19.43 Mil.
Total Assets was $27.24 Mil.
Property, Plant and Equipment(Net PPE) was $4.63 Mil.
Depreciation, Depletion and Amortization(DDA) was $2.62 Mil.
Selling, General, & Admin. Expense(SGA) was $24.45 Mil.
Total Current Liabilities was $30.86 Mil.
Long-Term Debt & Capital Lease Obligation was $0.21 Mil.
Net Income was -1.428 + -2.798 + -6.485 + -5.326 = $-16.04 Mil.
Non Operating Income was -0.116 + 1.028 + -1.318 + 0.338 = $-0.07 Mil.
Cash Flow from Operations was -4.472 + -0.734 + -5.938 + -2.283 = $-13.43 Mil.
Total Receivables was $4.39 Mil.
Revenue was 10.921 + 14.286 + 10.467 + 14.051 = $49.73 Mil.
Gross Profit was 3.746 + 6.118 + 3.337 + 3.596 = $16.80 Mil.
Total Current Assets was $27.78 Mil.
Total Assets was $38.75 Mil.
Property, Plant and Equipment(Net PPE) was $7.77 Mil.
Depreciation, Depletion and Amortization(DDA) was $2.26 Mil.
Selling, General, & Admin. Expense(SGA) was $31.64 Mil.
Total Current Liabilities was $19.78 Mil.
Long-Term Debt & Capital Lease Obligation was $12.30 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(3.53 / 46.026) / (4.388 / 49.725)
=0.076696 / 0.088245
=0.8691

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(16.797 / 49.725) / (15.851 / 46.026)
=0.337798 / 0.344392
=0.9809

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (19.428 + 4.627) / 27.241) / (1 - (27.782 + 7.767) / 38.745)
=0.116956 / 0.082488
=1.4179

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=46.026 / 49.725
=0.9256

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(2.261 / (2.261 + 7.767)) / (2.62 / (2.62 + 4.627))
=0.225469 / 0.361529
=0.6237

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(24.445 / 46.026) / (31.643 / 49.725)
=0.531113 / 0.63636
=0.8346

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0.211 + 30.859) / 27.241) / ((12.302 + 19.782) / 38.745)
=1.14056 / 0.828081
=1.3774

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-16.037 - -0.068 - -13.427) / 27.241
=-0.093315

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Biolase has a M-score of -3.08 suggests that the company is unlikely to be a manipulator.


Biolase Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Biolase's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Biolase Business Description

Traded in Other Exchanges
N/A
Address
27042 Towne Centre Drive, Suite 270, Lake Forest, CA, USA, 92610
Biolase Inc is a United States-based provider of laser systems for the dental industry. It develops, manufactures, markets, and sells laser systems in dentistry and medicine. The company offers two categories of laser system products: Waterlase (all-tissue) systems and Diode (soft-tissue) systems which allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a broad range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications. The majority of the company's revenue comes from the United States.
Executives
Goldman Sachs & Co. Llc 10 percent owner 200 WEST STREET, NEW YORK NY 10282
Goldman Sachs Group Inc 10 percent owner 200 WEST STREET, NEW YORK NY 10282
Lord Jonathan T Md director 500 WEST MAIN ST., LOUISVILLE KY 40202
Jennifer Bright officer: Chief Financial Officer 27042 TOWNE CENTRE DRIVE,, SUITE 270, FOOTHILL RANCH CA 92610
Steven Sandor officer: Chief Operating Officer 27042 TOWNE CENTRE DRIVE,, SUITE 270, FOOTHILL RANCH CA 92610
Jess Roper director 5555 OBERLIN DRIVE, SAN DIEGO CA 92121
Kenneth P. Yale director 27042 TOWN CENTRE DRIVE, SUITE 270, FOOTHILL RANCH CA 92610
John R Beaver director, officer: President & CEO C/O STERLING CHEMICALS INC, 1200 SMITH STREET, HOUSTON TX 77002
Kathleen T Oloughlin director 27042 TOWN CENTRE DRIVE, SUITE 270, FOOTHILL RANCH CA 92610
Somerman Martha J. Dds, Phd director 27042 TOWN CENTRE DRIVE, SUITE 270, FOOTHILL RANCH CA 92610
Summerhays Carol Gomez Dds director 27042 TOWN CENTRE DRIVE, SUITE 270, FOOTHILL RANCH CA 92610
Family Foundation Schuler 10 percent owner 100 N. FIELD DRIVE, SUITE 360, LAKE FOREST IL 60045
Larry N Feinberg 10 percent owner C/O ORACLE PARTNERS L P, 200 GREENWICH AVENUE, GREENWICH CT 06830
Jack W Schuler 10 percent owner 100 N. FIELD DRIVE, SUITE 360, LAKE FOREST IL 60045
Michael Ditolla director 3299 CAMBRIDGE AVE, BRONX NY 10463